The improved kidney risk score in ANCA-associated vasculitis for clinical practice and trials
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F24%3A00084587" target="_blank" >RIV/00023001:_____/24:00084587 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11110/24:10475717 RIV/00064165:_____/24:10475717
Result on the web
<a href="https://journals.lww.com/jasn/abstract/2024/03000/the_improved_kidney_risk_score_in_anca_associated.9.aspx" target="_blank" >https://journals.lww.com/jasn/abstract/2024/03000/the_improved_kidney_risk_score_in_anca_associated.9.aspx</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1681/ASN.0000000000000274" target="_blank" >10.1681/ASN.0000000000000274</a>
Alternative languages
Result language
angličtina
Original language name
The improved kidney risk score in ANCA-associated vasculitis for clinical practice and trials
Original language description
Background Reliable prediction tools are needed to personalize treatment in ANCA-associated GN. A retrospective international longitudinal cohort was collated to revise the ANCA renal risk score. Methods The primary end point was ESKD with patients censored at last follow-up. Cox proportional hazards were used to reweight risk factors. Kaplan-Meier curves, Harrell's C statistic, receiver operating characteristics, and calibration plots were used to assess model performance. Results Of 1591 patients, 1439 were included in the final analyses, 2:1 randomly allocated per center to development and validation cohorts (52% male, median age 64 years). In the development cohort (n=959), the ANCA renal risk score was validated and calibrated, and parameters were reinvestigated modifying interstitial fibrosis and tubular atrophy allowing semiquantitative reporting. An additional cutoff for kidney function (K) was identified, and serum creatinine replaced GFR (K0: <250 mmol/L=0, K1: 250-450 mmol/L=4, K2: >450 mmol/L=11 points). The risk points for the percentage of normal glomeruli (N) and interstitial fibrosis and tubular atrophy (T) were reweighted (N0: >25%=0, N1: 10%-25%=4, N2: <10%=7, T0: none/mild or <25%=0, T1: >= mild-moderate or >= 25%=3 points), and four risk groups created: low (0-4 points), moderate (5-11), high (12-18), and very high (21). Discrimination was C=0.831, and the 3-year kidney survival was 96%, 79%, 54%, and 19%, respectively. The revised score performed similarly well in the validation cohort with excellent calibration and discrimination (n=480, C=0.821). Conclusions The updated score optimizes clinicopathologic prognostication for clinical practice and trials.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30217 - Urology and nephrology
Result continuities
Project
—
Continuities
N - Vyzkumna aktivita podporovana z neverejnych zdroju
Others
Publication year
2024
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Journal of the American Society of Nephrology
ISSN
1046-6673
e-ISSN
1533-3450
Volume of the periodical
35
Issue of the periodical within the volume
3
Country of publishing house
US - UNITED STATES
Number of pages
12
Pages from-to
335-346
UT code for WoS article
001151732000001
EID of the result in the Scopus database
2-s2.0-85186319182